138 completed, 31 unknown, 9 recruiting, 9 terminated. 202 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 202 | Completed 138, Unknown 31, Recruiting 9, Terminated 9, Not yet recruiting 7, Withdrawn 5, Suspended 2, Active not recruiting 1 |
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria Coartem® Baby - Malaria | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 20 | 2027-06-18 | 2026-07-20 |
| Humanitarian Evaluation of Spatial Emanators for Malaria Control Guardian™ long-lasting spatial emanators - Malaria Infection | Phase 4 | Not yet recruiting | The Mentor Initiative | 32584 | 2026-10-26 | 2026-10-21 |
| Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission dihydroartemisinin-piperaquine - Malaria | Phase 4 | Not yet recruiting | University of California, San Francisco | 4800 | 2026-09-28 | 2026-09-11 |
| Perennial Malaria Chemoprevention in the Malaria Vaccine Era Sulfadoxine pyrimethamine + Amodiaquine, Dihydroartemisinin Piperaquine, Dihydroartemisinin Piperaquine Placebo - Malaria, Falciparum | Phase 4 | Not yet recruiting | Stanford University | 1290 | 2026-09-01 | 2026-01-07 |
| R21/MM Dosing, Presentations, and Preservatives 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative - Plasmodium Falciparum Malaria, Malaria | Phase 4 | Not yet recruiting | University of Oxford | 375 | 2026-08-15 | 2026-08-04 |
| Tafenoquine and ACTs (TADORE- Plus) Tafenoquine plus DHA-Piperaquine, Tafenoquine plus Artesunate-pyronaridine - Vivax Malaria | Phase 4 | Not yet recruiting | Menzies School of Health Research | 507 | 2026-06-01 | 2026-03-18 |
| Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine - Uncomplicated Malaria | Phase 4 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-02-12 |
| OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa Artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ) - Malaria, Hiv | Phase 4 | Recruiting | Yale University | 380 | 2025-12-18 | 2026-02-04 |
| Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat - Pharmacokinetics of Tafenoquine | Phase 4 | Recruiting | Curtin University | 30 | 2025-10-20 | 2026-03-18 |
| Post-discharge Malaria Chemoprevention Implementation Trial in Benin Adherence support strategy A, Adherence support strategy B, Control - Severe Malaria, Severe Anaemia | Phase 4 | Recruiting | Institut de Recherche Clinique du Benin | 648 | 2025-07-02 | 2026-08-12 |
| Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad "Synchronised" arm (intervention) - Malaria Infection, Malaria Vaccines | Phase 4 | Recruiting | Epicentre | 70000 | 2025-06-16 | 2026-04-15 |
| Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months - Malaria Vaccine | Phase 4 | Recruiting | Epicentre | 40000 | 2025-06-10 | 2025-08-08 |
| Vivax Elimination With Tafenoquine (VET) Study Tafenoquine - Malaria, Malaria, Vivax | Phase 4 | Completed | Shoklo Malaria Research Unit | 1242 | 2025-02-19 | 2026-01-06 |
| Mass Vaccine and Drug Administration, Bangladesh DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™ - Plasmodium Falciparum Malaria | Phase 4 | Recruiting | University of Oxford | 10000 | 2025-02-15 | 2025-12-18 |
| Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine - Malaria,Falciparum, Anemia in Children | Phase 4 | Completed | Liverpool School of Tropical Medicine | 788 | 2024-10-14 | 2026-07-30 |
| Southeast Asia Dose Optimization of Tafenoquine Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria | Phase 4 | Recruiting | University of Oxford | 820 | 2024-07-22 | 2026-10-09 |
| The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children Mosquirixs, artemether-lumefantrine - Malaria,Falciparum | Phase 4 | Unknown | Kamuzu University of Health Sciences | 5400 | 2024-06-01 | 2024-05-21 |
| The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy Artemether-lumefantrine, Dihydroartemisinin-Piperaquine - Falciparum; Malaria | Phase 4 | Completed | Infectious Diseases Research Collaboration, Uganda | 160 | 2024-05-28 | 2026-07-06 |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). - Vivax Malaria, G6PD Deficiency | Phase 4 | Recruiting | Menzies School of Health Research | 100 | 2024-05-17 | 2026-03-12 |
| Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique Sulfadoxine/pyrimethamine plus amodiaquine - Malaria,Falciparum, Chemoprevention | Phase 4 | Unknown | Malaria Consortium | 1000 | 2024-03-26 | 2024-03-29 |
Showing 20 of 202. Sign in to see all of them.
Malaria, Falciparum (61) · Malaria, Vivax (24) · Anemia (10) · HIV Infections (7) · Disease (6) · Pneumonia (5) · Acquired Immunodeficiency Syndrome (4) · Diarrhea (4) · Fever (3) · Glucosephosphate Dehydrogenase Deficiency (3) · Recurrence (3) · Bacterial Infections (2) · Birth Weight (2) · Malnutrition (2)
Mosquito-Borne Diseases (202) · Protozoan Infections (202) · Vector Borne Diseases (202) · Infections (201) · Parasitic Diseases (201) · Pathological Conditions, Signs and Symptoms (20) · Hemic and Lymphatic Diseases (14) · Hematologic Diseases (13) · Pathologic Processes (13) · Urogenital Diseases (13) · Immune System Diseases (12) · Communicable Diseases (11) · Genital Diseases (11) · Sexually Transmitted Diseases (11)
Artemether, Lumefantrine Drug Combination (70) · Primaquine (25) · Chloroquine (23) · fanasil, pyrimethamine drug combination (22) · amodiaquine, artesunate drug combination (19) · Amodiaquine (18) · Artesunate (17) · tafenoquine (7) · Mefloquine (6) · Pyrimethamine (6) · Rapid Diagnostic Tests (6) · atovaquone, proguanil drug combination (6) · Quinine (5) · Sulfadoxine (5) · Artemether (4)
London School of Hygiene and Tropical Medicine (16) · Centers for Disease Control and Prevention (13) · Bandim Health Project (8) · University of California, San Francisco (8) · University of Oxford (8) · Menzies School of Health Research (7) · Malaria Consortium (6) · Epicentre (5) · Sanofi (5) · Armed Forces Research Institute of Medical Sciences, Thailand (4) · Karolinska University Hospital (4) · PATH (4) · Albert Schweitzer Hospital (3) · Centre Muraz (3) · Centro de Investigacao em Saude de Manhica (3)
Tanzania (20) · Uganda (17) · Burkina Faso (14) · Kenya (14) · Ghana (13) · Malawi (11) · Cambodia (8) · Guinea-Bissau (8) · Democratic Republic of the Congo (7) · Thailand (7) · Vietnam (7) · Ethiopia (6) · Indonesia (6) · Papua New Guinea (6) · Gabon (5)
Andreas Martensson, PhD (3) · Harry Tagbor, DrPH (3) · Mariusz Wojnarski, MD (3) · Peter Aaby (3) · Salim Abdulla, MD, PhD (3) · Wilfred Fon Mbacham, PhD (3) · Andreas Martensson (2) · Brioni R Moore, PhD (2) · Christopher Whitty, FRCP (2) · Dysoley Lek, MD (2) · Francesco Grandesso, MSc (2) · Gauthier Mesia Kahunu, PhD (2)
PMID 25421474, PMID 18828899, PMID 30860013, PMID 39324693, PMID 11103309, PMID 16163624, PMID 17093247, PMID 17259188, PMID 17467344, PMID 17550470, PMID 18008241, PMID 18008242, PMID 18067679, PMID 18503714, PMID 18575626, PMID 18831691, PMID 18831737, PMID 19102746, PMID 19127975, PMID 19399156, PMID 19848610, PMID 20207689, PMID 20299957, PMID 20932805, PMID 2096501, PMID 21148503, PMID 21304921, PMID 21410954, PMID 21569596, PMID 21631932, PMID 21838909, PMID 21947399, PMID 22185672, PMID 22232457, PMID 22514617, PMID 22531245, PMID 22554092, PMID 22882836, PMID 23175563, PMID 23212366, PMID 23617626, PMID 24079295, PMID 24079992, PMID 24215306, PMID 24678612, PMID 24736370, PMID 24948695, PMID 25075834, PMID 25224002, PMID 25428714
R01HD068174 (3), 5UM1AI148689-03 (1), R01AI103228 (1), R01HD079695 (1), R01HL134211 (1), U01AI068632 (1), U01AI162463 (1), U01AI186861 (1)